Last reviewed · How we verify
NCT04278235
Expanded Access to Elezanumab
trial testing Elezanumab in Acute Spinal Cord Injury (SCI). Available.
Quick facts
| Lead sponsor | AbbVie |
|---|---|
| Status | AVAILABLE |
| Study type | EXPANDED_ACCESS |
Drugs / interventions tested
- Elezanumab — full drug profile →
Conditions studied
- Acute Spinal Cord Injury (SCI) — all drugs for Acute Spinal Cord Injury (SCI) →
Sponsor
AbbVie — full company profile →
Who can join
18 and older, any sex, with Acute Spinal Cord Injury (SCI). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to Elezanumab prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Neuroplasticity and regeneration after spinal cord injury.
Punjani N, Deska-Gauthier D, Hachem LD, Abramian M, et al · · 2023 · cited 19× · PMID 37416090 · DOI 10.1016/j.xnsj.2023.100235 -
Bridging the gap: a translational perspective in spinal cord injury.
Hassan OI, Takamiya S, Asgarihafshejani A, Fehlings MG. · · 2024 · cited 4× · PMID 39391076 · DOI 10.3389/ebm.2024.10266
Verify or expand the search:
- PubMed search for NCT04278235
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Elezanumab
Trials testing the same drug.
- NCT04309474 — A Safety and Efficacy Study of Intravenous (IV) Elezanumab Assessing Change in Neurologic Function in Adult Participants · Phase 2 · completed
- NCT04295538 — Safety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity Motor Sco · Phase 2 · completed
Other recruiting trials for Acute Spinal Cord Injury (SCI)
Currently open trials in the same condition.
- NCT07090473 — Safety of Transcutaneous Electrical Stimulation Potentiating Recovery in Acute Spinal Cord Injury Syndromes · NA · recruiting
Other AbbVie trials
Trials by the same sponsor.
- NCT07219017 — A Study to Assess the Mass Balance of Oral ABBV-1354 in Healthy Adult Male Participants · Phase 1 · completed
- NCT05316220 — A Study to Assess Adverse Events and Change in Disease Condition of Mesalamine Capsules in Children Aged 5 to 17 Years W · Phase 3 · withdrawn
- NCT07024797 — Study to Assess the Adverse Events, Tolerability, and How Oral Doses of ABBV-932 Moves Through the Body in Healthy Adult · Phase 1 · completed
- NCT07058051 — Cross-sectional Study to Characterize Real World Burden of Disease in Patients With Vitiligo in China · completed
- NCT07007091 — A Study to Assess the Relative Bioavailability of Risankizumab Following Subcutaneous Administrations With a Pre-Filled · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04278235 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by AbbVie
- Last refreshed: 3 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04278235.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing